Research & Development

What is AbIMP® Technology?

AbIMP® is a novel discovery platform that utilises monoclonal antibodies as selective inhibitors of previously intractable metzincin protease targets thereby offering new possibilities… Read more »

The ADAMs Family of Sheddases – Emerging Therapeutic Targets

The ADAMs gene family of cellular sheddases are exciting, new therapeutic targets and biomarkers emerging within several clinical arenas. ADAM is an acronym… Read more »

ADAM15, A Novel Target for Anti-angiogenesis Therapy

ADAM15 is a “sheddase” known to promote pathological angiogenesis in models of ocular neovascular disease and whose expression correlates strongly with the progression… Read more »

News

VASGEN Wins Therapy Accelerator Funding

August 19th, 2022

London UK, 19th  August 2022: Vasgen Limited (“Vasgen” or “the Company”), a speciality biotech company, reports successfully competing in the Hertfordshire Science Partnership… Read more »

VASGEN Achieves Proof of Concept for Pre-Clinical Ocular R & D Programme-Two Further Patents Granted

July 17th, 2017

London UK, 17th July 2017: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has successfully completed proof… Read more »

VASGEN Shortlisted to Present at Innovate UK Health & Life Science Investment Showcase

May 4th, 2016

London UK, May 4th 2016: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has been shortlisted to… Read more »